Anergent Pharmaceuticals Inc. Information

Summary. Anergent has developed medical device technology that delivers drugs via the oral (buccal) mucosa for comparable or faster onset of activity than intramuscular (IM) injection, without first pass through the liver. Delivering drugs via the buccal mucosa (inner cheeks and gums) is well-established with a self-applied patch. Our proprietary muco-adhesive formulation protects the drug from saliva while it is pushed into the bloodstream, eliminating the need for a physical patch. Our patented single use applicator requires no training, no patient prep, and no direct patient contact. Our platform technology is suitable for dozens of drugs where urgent onset is required and the patient is partially or fully incapacitated by age (pediatric and geriatric) or condition (seizure, shock, unconsciousness, overdose, emesis, nausea). The first use case is an easier to use, lower cost alternative to the Narcan® brand of naloxone, addressing the rapidly growing $1B overdose rescue market. Technology. Anergent’s solution is a patented (issued April 2023) single use applicator coupled with a muco-adhesive solution that allows any individual, without training, to administer urgently needed medication without any patient prep or direct physical contact with the patient’s nose or mouth. Unlike nasal sprays, which require patients to be on their back and to have clear nasal passageways, buccal delivery can be utilized on patients regardless of their physical position, condition, or consciousness.